Kymera Therapeutics doses first participant in IRAK4 degrader trial
Kymera Therapeutics has dosed the first participant in a Phase 1 first-in-human trial of KT-485 (SAR447971), its oral second-generation IRAK4 protein degrader, triggering a $20 million milestone payment from collaboration partner Sanofi. The trial, registered as NCT07629336 and conducted by Sanofi, is evaluating the candidate in healthy adult volunteers and patients with hidradenitis suppurativa (HS), a chronic and often debilitating inflammatory skin condition.
KT-485 is being advanced under a broader Kymera–Sanofi collaboration covering IRAK4 degraders outside oncology. Sanofi is leading development, regulatory, and commercial activities, while Kymera retains an option to participate in a 50/50 US profit-share and receives double-digit tiered royalties in the rest of the world. The Watertown, Massachusetts-based company is eligible to receive up to $975 million in additional clinical, regulatory, and commercial milestones tied to the programme.
Trial design and mechanism
The Phase 1 study is structured in three parts: double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, plus an open-label MAD cohort. Investigators will assess safety, tolerability, and pharmacokinetics alongside exploratory endpoints.
IRAK4 is a scaffolding kinase central to the myddosome complex, which mediates signalling through IL-1 and Toll-like receptors. Its position at the interface of innate and adaptive immunity makes it an attractive target across a range of immuno-inflammatory conditions. Kymera argues that full degradation of IRAK4 — neutralising both its kinase activity and its scaffolding function — offers broader anti-inflammatory potential than kinase inhibition alone, which is the approach taken by several earlier-generation candidates that failed or showed limited benefit in clinical settings.
"There remains a significant need for novel oral options that can address key inflammatory pathways implicated in several immuno-inflammatory conditions," said Nello Mainolfi, founder, president and chief executive of Kymera, describing KT-485 as the company's second-generation IRAK4 degrader, implying improved potency and selectivity over earlier work.
Market context and competitive landscape
The IRAK4 space has seen considerable activity over the past several years, with both small-molecule inhibitors and, more recently, degraders attracting investment. Pfizer and AstraZeneca have each advanced IRAK4 inhibitors through clinical programmes for inflammatory indications, with mixed results that underscored the difficulty of achieving adequate target engagement without off-target effects. Degrader-based approaches, which employ targeted protein degradation (TPD) technology to eliminate the protein rather than merely block it, are positioned by their developers as a way to overcome these limitations — though human validation data in this modality remains limited.
Kymera's own first-generation IRAK4 degrader, KT-474, demonstrated proof-of-concept degradation in patients, providing some mechanistic confidence ahead of the KT-485 programme. The HS indication is a logical entry point: the condition has few approved systemic options, and the regulatory precedent set by IL-17 and IL-23 inhibitors in inflammatory skin disease suggests an amenable pathway for novel agents that demonstrate robust efficacy and a clean safety profile.
With Sanofi bearing the clinical and regulatory costs for KT-485, Kymera's financial exposure is limited while the milestone and royalty structure offers meaningful upside. Investors will track Phase 1 safety readouts — particularly any signals around tolerability and degrader-related off-target effects — as the key determinants of whether the programme advances into a registrational study. Given the breadth of immuno-inflammatory conditions potentially addressable by IRAK4 degradation, the indication selection for Phase 2 will be watched closely as a signal of Sanofi's commercial priorities for the asset.